|
US20040087498A1
(en)
*
|
1991-02-28 |
2004-05-06 |
Novo Nordisk Health Care Ag |
Modified factor VII
|
|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
|
AU8101698A
(en)
*
|
1997-07-18 |
1999-02-10 |
Novo Nordisk A/S |
Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
|
|
US6693075B1
(en)
*
|
1997-10-23 |
2004-02-17 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US7247708B2
(en)
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6406488B1
(en)
*
|
1998-08-27 |
2002-06-18 |
Heartstent Corporation |
Healing transmyocardial implant
|
|
EP0987274A1
(en)
|
1998-09-15 |
2000-03-22 |
Hoechst Marion Roussel Deutschland GmbH |
Factor VIIa Inhibitors
|
|
EP1059302A1
(en)
|
1999-06-08 |
2000-12-13 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitors
|
|
US6924359B1
(en)
*
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
|
EP1095933A1
(en)
|
1999-10-30 |
2001-05-02 |
Aventis Pharma Deutschland GmbH |
Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
|
|
EP1982732A3
(en)
|
2000-02-11 |
2011-06-08 |
Bayer HealthCare LLC |
Factor VII or VIIA-like conjugates
|
|
EP1274720A4
(en)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
FUSION PROTEINS CONTAINING ALBUMIN
|
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
EP1162194A1
(en)
|
2000-06-06 |
2001-12-12 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
|
|
WO2001097752A2
(en)
*
|
2000-06-20 |
2001-12-27 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising urokinase for modulating muscle contractility and angiogenisis
|
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
|
US7160540B2
(en)
*
|
2000-06-30 |
2007-01-09 |
Regents Of The University Of Minnesota |
Methods for detecting activity of clottings factors
|
|
US20030211094A1
(en)
*
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
|
PL362320A1
(en)
|
2000-12-06 |
2004-10-18 |
Aventis Pharma Deutschland Gmbh |
Guanidine and amidine derivatives as factor xa inhibitors
|
|
US6825323B2
(en)
*
|
2001-01-10 |
2004-11-30 |
The United States Of America As Represented By The Secretary Of The Army |
Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
|
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
|
IL157842A0
(en)
*
|
2001-03-22 |
2004-03-28 |
Novo Nordisk Healthcare Ag |
Coagulation factor vii derivatives
|
|
IL158615A0
(en)
*
|
2001-05-02 |
2004-05-12 |
Novo Nordisk As |
Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
|
|
EP1270551A1
(en)
|
2001-06-26 |
2003-01-02 |
Aventis Pharma Deutschland GmbH |
Urea derivatives with antiproteolytic activity
|
|
WO2003022122A2
(en)
*
|
2001-09-10 |
2003-03-20 |
Florence Medical Ltd. |
Individual ffr determination for lesions of a multi-lesioned blood vessel
|
|
EP2042196B1
(en)
|
2001-10-10 |
2016-07-13 |
ratiopharm GmbH |
Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
WO2003037361A2
(en)
*
|
2001-11-02 |
2003-05-08 |
Novo Nordisk Health Care Ag |
Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
|
|
EP1314733A1
(en)
|
2001-11-22 |
2003-05-28 |
Aventis Pharma Deutschland GmbH |
Indole-2-carboxamides as factor Xa inhibitors
|
|
RU2357751C2
(ru)
*
|
2001-12-21 |
2009-06-10 |
Ново Нордиск Хелт Кэр Аг |
Жидкая композиция полипептидов фактора vii
|
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
|
EP1458407A1
(en)
*
|
2001-12-21 |
2004-09-22 |
Novo Nordisk A/S |
Liquid composition of modified factor vii polypeptides
|
|
US7700733B2
(en)
*
|
2002-04-30 |
2010-04-20 |
Bayer Healthcare Llc |
Factor VII or VIIa polypeptide variants
|
|
EP1503798B8
(en)
*
|
2002-05-03 |
2012-03-14 |
Novo Nordisk Health Care AG |
Stabilised solid compositions of modified factor vii
|
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
|
BRPI0311959B8
(pt)
|
2002-06-21 |
2021-05-25 |
Novo Nordisk Healthcare Ag |
composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
|
|
EP1549677B1
(en)
*
|
2002-09-30 |
2011-04-13 |
Bayer HealthCare LLC |
FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
|
|
US7358268B2
(en)
|
2002-12-04 |
2008-04-15 |
Sanofi-Aventis Deutschland Gmbh |
Imidazole derivatives as factor Xa inhibitors
|
|
US7429581B2
(en)
|
2002-12-23 |
2008-09-30 |
Sanofi-Aventis Deutschland Gmbh |
Pyrazole-derivatives as factor Xa inhibitors
|
|
US20040176704A1
(en)
*
|
2003-03-04 |
2004-09-09 |
Stevens Timothy A |
Collection device adapted to accept cartridge for point of care system
|
|
AU2004222625A1
(en)
*
|
2003-03-18 |
2004-09-30 |
Novo Nordisk Health Care Ag |
Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
|
|
DK2085470T3
(da)
*
|
2003-03-20 |
2012-08-06 |
Bayer Healthcare Llc |
FVII- eller FVIIa-varianter
|
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
NZ542586A
(en)
|
2003-04-09 |
2009-11-27 |
Biogenerix Ag |
Method of forming a covalent conjugate between a G-CSF peptide and PEG
|
|
US20040202726A1
(en)
*
|
2003-04-10 |
2004-10-14 |
Deshay Samuel L. |
Topical blood pressure composition
|
|
EP1479675A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Indazole-derivatives as factor Xa inhibitors
|
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
|
US7317027B2
(en)
|
2003-05-19 |
2008-01-08 |
Sanofi-Aventis Deutschland Gmbh |
Azaindole-derivatives as factor Xa inhibitors
|
|
US7741341B2
(en)
|
2003-05-19 |
2010-06-22 |
Sanofi-Aventis Deutschland Gmbh |
Benzimidazole-derivatives as factor Xa inhibitors
|
|
US7223780B2
(en)
|
2003-05-19 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
|
|
EP1479680A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Azaindole derivatives as Factor Xa inhibitors
|
|
RU2364609C2
(ru)
*
|
2003-05-23 |
2009-08-20 |
Ново Нордиск Хелт Кэр Аг |
Стабилизация белка в растворе
|
|
US7029675B1
(en)
*
|
2003-06-04 |
2006-04-18 |
Shu-Wha Lin |
Hepsin antagonist and methods of use
|
|
DK1644504T3
(da)
*
|
2003-06-19 |
2010-05-25 |
Bayer Healthcare Llc |
Faktor VII- eller -VIIA-Gla-domænevarianter
|
|
WO2004112828A1
(en)
|
2003-06-25 |
2004-12-29 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
|
ATE446768T1
(de)
*
|
2003-07-01 |
2009-11-15 |
Novo Nordisk Healthcare Ag |
Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
|
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
|
AU2004264282B2
(en)
|
2003-08-14 |
2010-10-14 |
Novo Nordisk Health Care Ag |
Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
KR20150138427A
(ko)
*
|
2003-12-19 |
2015-12-09 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
|
|
EP1568698A1
(en)
|
2004-02-27 |
2005-08-31 |
Aventis Pharma Deutschland GmbH |
Pyrrole-derivatives as factor Xa inhibitors
|
|
JP2008514216A
(ja)
*
|
2004-09-29 |
2008-05-08 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Ｄｅｓｇｌａ−ｖｉｉ因子ポリペプチド構造の除去による、ｖｉｉ因子ポリペプチドの原体の精製
|
|
EP3061461A1
(en)
|
2004-10-29 |
2016-08-31 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
US9029331B2
(en)
|
2005-01-10 |
2015-05-12 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
|
EP1871795A4
(en)
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
US20080242607A1
(en)
|
2006-07-21 |
2008-10-02 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
|
CN101796063B
(zh)
|
2007-04-03 |
2017-03-22 |
拉蒂奥法姆有限责任公司 |
使用糖聚乙二醇化g‑csf的治疗方法
|
|
US9493499B2
(en)
|
2007-06-12 |
2016-11-15 |
Novo Nordisk A/S |
Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
|
|
DK2257311T3
(da)
|
2008-02-27 |
2014-06-30 |
Novo Nordisk As |
Konjugerede Faktor VIII-Molekyler
|
|
CA2747721C
(en)
|
2008-12-19 |
2021-07-20 |
Baxter International Inc. |
Tfpi inhibitors and methods of use
|
|
CN102741275B
(zh)
|
2009-08-24 |
2016-08-03 |
阿穆尼克斯运营公司 |
凝血因子ix组合物及其制备和使用方法
|
|
EP2547355B1
(en)
|
2010-03-19 |
2017-01-11 |
Baxalta GmbH |
Tfpi inhibitors and methods of use
|
|
KR101294351B1
(ko)
*
|
2010-05-27 |
2013-08-07 |
동국대학교 산학협력단 |
뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
|
|
LT3564260T
(lt)
|
2012-02-15 |
2023-01-10 |
Bioverativ Therapeutics Inc. |
Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
|
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
EP2827883B1
(en)
|
2012-03-21 |
2019-05-08 |
Baxalta GmbH |
Tfpi inhibitors and methods of use
|
|
TWI667255B
(zh)
|
2013-08-14 |
2019-08-01 |
美商生物化學醫療公司 |
因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
|
|
SG11201605242YA
(en)
|
2014-01-10 |
2016-07-28 |
Biogen Ma Inc |
Factor viii chimeric proteins and uses thereof
|
|
MX2018000869A
(es)
*
|
2015-07-22 |
2018-07-06 |
Iconic Therapeutics Inc |
Metodos para tratar trastornos asociados con la angiogenesis y la neovascularizacion.
|
|
IL257231B
(en)
|
2015-08-03 |
2022-09-01 |
Bioverativ Therapeutics Inc |
Factor ix fusion proteins and methods of making and using same
|
|
DK3402537T3
(da)
|
2016-01-15 |
2021-03-29 |
Rigshospitalet |
Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII
|
|
US20190358351A1
(en)
|
2016-11-17 |
2019-11-28 |
Minerva Imaging Aps |
177-lu labeled active site inhibited factor vii
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
SI3793588T1
(sl)
|
2018-05-18 |
2025-07-31 |
Bioverativ Therapeutics Inc. |
Postopki zdravljenja hemofilije A
|